Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Choline | 20 | 2019 | 59 | 7.270 |
Why?
|
| Liver Neoplasms | 14 | 2023 | 190 | 4.170 |
Why?
|
| Carcinoma, Hepatocellular | 14 | 2023 | 145 | 3.490 |
Why?
|
| Positron-Emission Tomography | 14 | 2015 | 80 | 3.450 |
Why?
|
| Radiopharmaceuticals | 10 | 2018 | 55 | 2.590 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2017 | 214 | 2.570 |
Why?
|
| Prostatic Neoplasms | 12 | 2015 | 935 | 2.020 |
Why?
|
| Prostate-Specific Antigen | 3 | 2016 | 118 | 1.190 |
Why?
|
| Fluorine Radioisotopes | 7 | 2018 | 11 | 1.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2015 | 3 | 1.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2015 | 3 | 1.050 |
Why?
|
| Liver Transplantation | 2 | 2023 | 30 | 0.900 |
Why?
|
| Aged | 23 | 2020 | 6741 | 0.860 |
Why?
|
| Aged, 80 and over | 14 | 2017 | 2379 | 0.790 |
Why?
|
| Radium | 2 | 2017 | 2 | 0.760 |
Why?
|
| Liver | 3 | 2019 | 479 | 0.740 |
Why?
|
| Male | 33 | 2020 | 20025 | 0.700 |
Why?
|
| Middle Aged | 24 | 2020 | 10129 | 0.690 |
Why?
|
| Whole Body Imaging | 3 | 2016 | 25 | 0.670 |
Why?
|
| Humans | 40 | 2023 | 37093 | 0.660 |
Why?
|
| Neoplasms | 2 | 2023 | 1103 | 0.580 |
Why?
|
| Phospholipids | 1 | 2017 | 70 | 0.560 |
Why?
|
| Brain Neoplasms | 3 | 2007 | 111 | 0.560 |
Why?
|
| Survival Analysis | 5 | 2023 | 325 | 0.550 |
Why?
|
| Tomography, Emission-Computed | 2 | 2007 | 7 | 0.550 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 128 | 0.500 |
Why?
|
| Tumor Burden | 4 | 2016 | 77 | 0.480 |
Why?
|
| Choline Kinase | 1 | 2012 | 2 | 0.440 |
Why?
|
| Hexokinase | 1 | 2012 | 10 | 0.430 |
Why?
|
| Propensity Score | 2 | 2023 | 38 | 0.420 |
Why?
|
| Prospective Studies | 4 | 2021 | 1378 | 0.420 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 92 | 0.400 |
Why?
|
| Genetic Markers | 1 | 2012 | 142 | 0.400 |
Why?
|
| Splenosis | 1 | 2010 | 2 | 0.380 |
Why?
|
| Pheochromocytoma | 1 | 2010 | 11 | 0.380 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2010 | 17 | 0.380 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 52 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 182 | 0.360 |
Why?
|
| Spleen | 1 | 2010 | 199 | 0.360 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 14 | 0.360 |
Why?
|
| Hormones | 1 | 2009 | 55 | 0.340 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 562 | 0.330 |
Why?
|
| Disease Progression | 3 | 2017 | 601 | 0.330 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 13 | 0.330 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2010 | 289 | 0.310 |
Why?
|
| Hepatitis B, Chronic | 2 | 2020 | 10 | 0.300 |
Why?
|
| Female | 17 | 2020 | 20969 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 935 | 0.290 |
Why?
|
| DNA Methylation | 3 | 2016 | 325 | 0.280 |
Why?
|
| Hepatitis | 2 | 2016 | 9 | 0.270 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 219 | 0.270 |
Why?
|
| Image Enhancement | 1 | 2006 | 40 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 481 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2023 | 2026 | 0.260 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 61 | 0.260 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 275 | 0.260 |
Why?
|
| Hospitals, Community | 1 | 2004 | 12 | 0.250 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 583 | 0.240 |
Why?
|
| Glioblastoma | 1 | 2004 | 55 | 0.230 |
Why?
|
| Radionuclide Imaging | 2 | 2015 | 28 | 0.230 |
Why?
|
| Hepatectomy | 1 | 2023 | 5 | 0.230 |
Why?
|
| Prognosis | 3 | 2020 | 739 | 0.230 |
Why?
|
| Adult | 10 | 2020 | 11712 | 0.220 |
Why?
|
| Sample Size | 1 | 2023 | 25 | 0.220 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 4 | 0.200 |
Why?
|
| Hepatitis B virus | 2 | 2018 | 13 | 0.190 |
Why?
|
| Treatment Outcome | 2 | 2017 | 1369 | 0.190 |
Why?
|
| Hepacivirus | 2 | 2018 | 62 | 0.190 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 358 | 0.180 |
Why?
|
| ROC Curve | 3 | 2018 | 138 | 0.180 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 5 | 0.170 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1502 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2019 | 118 | 0.160 |
Why?
|
| Neutrophils | 1 | 2019 | 131 | 0.160 |
Why?
|
| Radioisotopes | 1 | 2017 | 16 | 0.150 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 441 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 89 | 0.150 |
Why?
|
| Hawaii | 4 | 2013 | 1929 | 0.140 |
Why?
|
| Tissue Extracts | 1 | 2016 | 10 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 3 | 2016 | 515 | 0.140 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 18 | 0.140 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2015 | 1 | 0.140 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 21 | 0.140 |
Why?
|
| Biliary Atresia | 1 | 2015 | 4 | 0.130 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2015 | 2 | 0.130 |
Why?
|
| Cholestasis | 1 | 2015 | 9 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 148 | 0.130 |
Why?
|
| Bile Acids and Salts | 1 | 2015 | 33 | 0.130 |
Why?
|
| Beta Particles | 1 | 2015 | 2 | 0.130 |
Why?
|
| Femur Head | 1 | 2015 | 3 | 0.130 |
Why?
|
| Alpha Particles | 1 | 2015 | 4 | 0.130 |
Why?
|
| Rectum | 1 | 2015 | 22 | 0.130 |
Why?
|
| Urinary Bladder | 1 | 2015 | 29 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 626 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1130 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 484 | 0.120 |
Why?
|
| Penis | 1 | 2015 | 90 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2015 | 208 | 0.120 |
Why?
|
| Time Factors | 2 | 2012 | 1742 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 560 | 0.120 |
Why?
|
| Prostate | 1 | 2015 | 154 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 39 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 67 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 6 | 0.110 |
Why?
|
| SEER Program | 1 | 2012 | 91 | 0.110 |
Why?
|
| Digestive System Neoplasms | 1 | 2012 | 4 | 0.110 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2012 | 10 | 0.100 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 26 | 0.100 |
Why?
|
| Electrophoresis, Microchip | 1 | 2012 | 21 | 0.100 |
Why?
|
| Recurrence | 1 | 2012 | 131 | 0.100 |
Why?
|
| Taxoids | 1 | 2012 | 37 | 0.100 |
Why?
|
| Splenectomy | 1 | 2010 | 8 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 400 | 0.090 |
Why?
|
| Phosphorylcholine | 1 | 2010 | 8 | 0.090 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 4 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2012 | 550 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2010 | 67 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 42 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 661 | 0.090 |
Why?
|
| Gene Expression | 1 | 2012 | 674 | 0.090 |
Why?
|
| alpha-Fetoproteins | 2 | 2020 | 31 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 45 | 0.080 |
Why?
|
| False Negative Reactions | 1 | 2008 | 9 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2010 | 167 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 60 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 803 | 0.080 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2007 | 17 | 0.080 |
Why?
|
| Cyclobutanes | 1 | 2007 | 2 | 0.080 |
Why?
|
| Carboxylic Acids | 1 | 2007 | 13 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 59 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2008 | 63 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2018 | 88 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 494 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2007 | 127 | 0.070 |
Why?
|
| Risk Factors | 3 | 2017 | 3562 | 0.070 |
Why?
|
| Retroperitoneal Space | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 1492 | 0.060 |
Why?
|
| Benchmarking | 1 | 2004 | 29 | 0.060 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 15 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2016 | 90 | 0.060 |
Why?
|
| Age Distribution | 1 | 2004 | 225 | 0.060 |
Why?
|
| Demography | 1 | 2004 | 175 | 0.060 |
Why?
|
| Genome, Human | 2 | 2016 | 135 | 0.060 |
Why?
|
| Gene Regulatory Networks | 2 | 2016 | 120 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2231 | 0.060 |
Why?
|
| Hypertension | 1 | 2010 | 796 | 0.060 |
Why?
|
| Rats | 1 | 2010 | 3483 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2017 | 336 | 0.050 |
Why?
|
| Young Adult | 1 | 2010 | 4268 | 0.050 |
Why?
|
| Biopsy | 1 | 2020 | 164 | 0.050 |
Why?
|
| China | 1 | 2020 | 196 | 0.040 |
Why?
|
| Ileum | 1 | 2019 | 15 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 15081 | 0.040 |
Why?
|
| Adolescent | 2 | 2010 | 5363 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 211 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 534 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 36 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2019 | 305 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2017 | 112 | 0.040 |
Why?
|
| Internet | 1 | 2018 | 211 | 0.040 |
Why?
|
| Brain | 1 | 2004 | 1346 | 0.030 |
Why?
|
| Cholangiography | 1 | 2015 | 2 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2015 | 8 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 19 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 30 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 238 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1354 | 0.030 |
Why?
|
| Metabolome | 1 | 2015 | 53 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 83 | 0.030 |
Why?
|
| Models, Biological | 1 | 2018 | 677 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1609 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1033 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2013 | 3 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2013 | 11 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 854 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 62 | 0.030 |
Why?
|
| CpG Islands | 1 | 2013 | 97 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 894 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 1046 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2012 | 67 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 474 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 922 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 940 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 44 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 1015 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2010 | 52 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 122 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 923 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2010 | 1418 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1455 | 0.020 |
Why?
|
| Child | 1 | 2010 | 3131 | 0.010 |
Why?
|